全文获取类型
收费全文 | 5534篇 |
免费 | 481篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 101篇 |
妇产科学 | 145篇 |
基础医学 | 977篇 |
口腔科学 | 104篇 |
临床医学 | 551篇 |
内科学 | 1181篇 |
皮肤病学 | 185篇 |
神经病学 | 793篇 |
特种医学 | 201篇 |
外科学 | 506篇 |
综合类 | 45篇 |
一般理论 | 4篇 |
预防医学 | 345篇 |
眼科学 | 138篇 |
药学 | 302篇 |
中国医学 | 8篇 |
肿瘤学 | 409篇 |
出版年
2024年 | 15篇 |
2023年 | 97篇 |
2022年 | 135篇 |
2021年 | 241篇 |
2020年 | 169篇 |
2019年 | 218篇 |
2018年 | 247篇 |
2017年 | 195篇 |
2016年 | 256篇 |
2015年 | 257篇 |
2014年 | 287篇 |
2013年 | 340篇 |
2012年 | 514篇 |
2011年 | 491篇 |
2010年 | 247篇 |
2009年 | 226篇 |
2008年 | 330篇 |
2007年 | 269篇 |
2006年 | 279篇 |
2005年 | 260篇 |
2004年 | 177篇 |
2003年 | 194篇 |
2002年 | 149篇 |
2001年 | 40篇 |
2000年 | 30篇 |
1999年 | 33篇 |
1998年 | 35篇 |
1997年 | 28篇 |
1996年 | 18篇 |
1995年 | 22篇 |
1994年 | 19篇 |
1993年 | 9篇 |
1992年 | 8篇 |
1991年 | 8篇 |
1990年 | 10篇 |
1989年 | 6篇 |
1988年 | 11篇 |
1987年 | 11篇 |
1986年 | 12篇 |
1985年 | 14篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1979年 | 6篇 |
1977年 | 14篇 |
1976年 | 10篇 |
1975年 | 12篇 |
1974年 | 5篇 |
1972年 | 9篇 |
1970年 | 6篇 |
1926年 | 5篇 |
排序方式: 共有6028条查询结果,搜索用时 31 毫秒
51.
Edward Chow Lori Holden Joel Rubenstein Monique Christakis Katharina Sixel Marjan Vidmar Joel Finkelstein Charles Hayter Andrew Loblaw Rebecca Wong Ewa Szumacher Cyril Danjoux 《Radiotherapy and oncology》2004,70(3):291-294
Twenty-five patients with osteolytic metastases had computed tomography (CT) scans before and 3 months after palliative radiotherapy. The median % density change following single 8 Gy, 20 Gy/5#, 30 Gy/10# were: 128 (range 98–255), 141 (79–342), and 145 (65–235), respectively. It is feasible to evaluate remineralization of osteolytic lesions with palliative radiotherapy. 相似文献
52.
Susanna Hegewisch-Becker Katharina Braun Markus Otte Aneta Corovic Djordje Atanackovic Axel Nierhaus Dieter K Hossfeld Klaus Pantel 《Clinical cancer research》2003,9(6):2079-2084
PURPOSE: Combining heat with antineoplastic drugs has produced evidence of antitumor synergism. An increasing number of trials are investigating whole body hyperthermia (WBH) in combination with chemotherapy in patients with advanced malignancies. Here we investigated whether the hyperdynamic state of the circulation as a consequence of WBH may stimulate dissemination of malignant cells. EXPERIMENTAL DESIGN: WBH in combination with chemotherapy was administered by a radiant heat device to 20 consecutive patients with advanced epithelial malignancies. One WBH session lasted for approximately 4 h (90 min heating time, 60 min plateau at 41.8 degrees C, and 60-80 min cooling). Peripheral blood was drawn before WBH treatment (baseline), at the end of the plateau (1 h), and 24 h and 48 h thereafter. After removal of leukocytes using anti-CD45 magnetic beads, circulating tumor cells were detected immunocytochemically using the monoclonal antibody A45-B/B3, which binds to a common epitope present on various cytokeratins. RESULTS: The method used to detect tumor cells in the peripheral blood proved to be specific and very sensitive (detection limit 1 tumor cell per 1.7 x 10(5) peripheral blood mononuclear cell). Before WBH, 6 of 20 patients had cyto-keratin-positive cells in their blood. A treatment-induced increase in the number of circulating tumor cells became statistically significant at 24 h after WBH (P = 0.043) and was detected in a total of 9 patients, 5 of whom had no detectable malignant cells at baseline. There was no evidence of a correlation between an increase in the number of circulating tumor cells and increased metastasis frequency. CONCLUSIONS: Our findings suggest that WBH might induce a temporary release of tumor cells into the circulation, but this spread appears to be clinically not significant in patients with advanced malignancies. 相似文献
53.
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. 总被引:2,自引:0,他引:2
Peter Jantscheff Luigi Terracciano Adam Lowy Katharina Glatz-Krieger Fritz Grunert Burkhard Micheel Jens Brümmer Urs Laffer Urs Metzger Richard Herrmann Christoph Rochlitz 《Journal of clinical oncology》2003,21(19):3638-3646
PURPOSE: CEACAM6, CEACAM1, and human carcinoembryonic antigen (CEA) are coexpressed in normal colorectal epithelia, but show deregulated expression in colorectal cancers (CRC). Upregulation of CEACAM6 expression in hyperplastic polyps and early adenomas represents one of the earliest observable molecular events leading to colorectal tumors. The aim of our study was to evaluate the prognostic relevance of CEACAM6, CEACAM1, and CEA tissue expression in patients with CRC. PATIENTS AND METHODS: Immunohistochemical analysis was carried out on tissue microarrays from 243 paraffin-embedded biopsies from a randomized controlled clinical trial (Swiss Group for Clinical Cancer Research [SAKK] 40/81) of adjuvant fluorouracil-based chemotherapy with CEACAM-specific monoclonal antibodies. The median follow-up was 8 years. Overall survival (OS) and disease-free survival (DFS) were calculated using Kaplan-Meier estimates and hazard ratios (HRs) estimated using Cox proportional hazards models. RESULTS: Tissue expression of CEACAM6, CEACAM1, and CEA was enhanced in 55%, 58%, and 94% of patients, respectively. Multivariate Cox analysis including sex, age, tumor site, stage, differentiation grade, treatment, and nodal status as covariates showed that CEACAM6 overexpression independently predicted poor OS (HR, 1.86; P =.0100) and DFS (HR, 2.00; P =.0028), whereas CEACAM1 or CEA were not significantly related to these outcomes. The data did not provide evidence for or against the hypothesis that the CEACAM6 effect on survival differs according to treatment. CONCLUSION: Expression of the cell adhesion molecule CEACAM6 in CRC is an independent prognostic factor allowing subdivision of patients into low- and high-risk groups. Whether CEACAM6 or CEA and CEACAM1 might be useful as predictive markers of chemotherapy benefit remains unclear. 相似文献
54.
55.
Health promotion (HP) amongst older people is an increasingly prominent policy concern for governments. The development of an evidence-base and the advocacy of effective interventions in the light of this act as legitimation tools for the overall HP phenomenon – assisting the growth of state and non-state funding for public health initiatives for older people. In structuring decision-making as to which individual projects/initiatives receive funding, frameworks for acknowledging efficacy impact on formats of HP work both positively and negatively. Drawing on recent research across the EU and focusing on the specific national contexts of Austria and England, this comparative policy analysis triangulates best-practice modelling, evaluation data and interviews with project coordinators to explore how policy contexts impact on the nature and format of HP interventions. Amidst a developing awareness of what effective practice looks like, successful HP initiatives must advocate their legitimacy within narrow rules of quality, where measurable outcomes have become the keys which unlock financial resources. Findings across both countries suggest that this instrumentalisation of legitimation, driven by economic pressures and bureaucratic generalisability, threatens the rationality of HP. From a Habermasian perspective, tensions emerge between projects’ remaining reflexive towards processes and their need to articulate the ‘success’ of the interventions in a language of outcomes. Over time, in an era where resources are increasingly scarce and competition over these intensifies, a danger exists whereby the instrumentality of HP begins to separate from, and impinge upon, the capacity for projects to think and act holistically. 相似文献
56.
Katharine Bray-French Katharina Hartman Guido Steiner Céline Marban-Doran Juliana Bessa Neil Campbell Meret Martin-Facklam Kay-Gunnar Stubenrauch Corinne Solier Thomas Singer Axel Ducret 《Journal of pharmaceutical sciences》2021,110(7):2575-2584
Biotherapeutics have revolutionized our ability to treat life-threatening diseases. Despite clinical success, the use of biotherapeutics has sometimes been limited by the immune response mounted against them in the form of anti-drug antibodies (ADAs). The multifactorial nature of immunogenicity has prevented a standardized approach for assessing this and each of the assessment methods developed so far does not exhibit high enough reliability to be used alone, due to limited predictiveness. This prompted the Roche Pharma Research and Early Development (pRED) Immunogenicity Working Group to establish an internal preclinical immunogenicity toolbox of in vitro/in vivo approaches and accompanying guidelines for a harmonized assessment and management of immunogenicity in early development. In this article, the complex factors influencing immunogenicity and their associated clinical ramifications are discussed to highlight the importance of an end-to-end approach conducted from lead optimization to clinical candidate selection. We then examine the impact of the resulting lead candidate categorization on the design and implementation of a multi-tiered ADA/immunogenicity assay strategy prior to phase I (entry into human) through early clinical development. Ultimately, the Immunogenicity Toolbox ensures that Roche pRED teams are equipped to address immunogenicity in a standardized manner, paving the way for lifesaving products with improved safety and efficacy. 相似文献
57.
58.
59.
Stefan Stefanovic Florian Schuetz Christof Sohn Philipp Beckhove Christoph Domschke 《Cancer metastasis reviews》2014,33(1):309-320
Breast cancer is a systemic disease with a primarily local component. Besides surgical resection and irradiation of the locoregional tumor setting, central therapeutic aim is the elimination of disseminated micrometastatic tumor cells using cytostatic and/or hormonal treatment. Nevertheless, in the course of time a majority of patients suffer from systemic recurrence in the form of distant metastases. Intriguingly, in this connection, intratumoral cytotoxic T lymphocytes might serve as independent predictors of treatment efficacy and clinical outcome. Loss of immune balance (tumor dormancy) during intensive cross talk between T cells and tumor cells in the bone marrow microenvironment is suggested one reason for distant metastatic relapse. In this clinical context, further supportive therapies become increasingly attractive, taking immunological features of breast cancer cells into special account. The present review aims to dissect bone marrow-derived cellular antitumor immune responses and translational immunologic treatment options regarding their actual relevance to patients’ clinical benefit and their future directions in breast cancer management. 相似文献